These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12359955)

  • 1. A chimeric mouse model of Gaucher disease.
    Beutler E; West C; Torbett BE; Deguchi H
    Mol Med; 2002 May; 8(5):247-50. PubMed ID: 12359955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease.
    Sinclair GB; Jevon G; Colobong KE; Randall DR; Choy FY; Clarke LA
    Mol Genet Metab; 2007 Feb; 90(2):148-56. PubMed ID: 17079175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse.
    Willemsen R; Tybulewicz V; Sidransky E; Eliason WK; Martin BM; LaMarca ME; Reuser AJ; Tremblay M; Westphal H; Mulligan RC
    Mol Chem Neuropathol; 1995; 24(2-3):179-92. PubMed ID: 7632321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene.
    Tybulewicz VL; Tremblay ML; LaMarca ME; Willemsen R; Stubblefield BK; Winfield S; Zablocka B; Sidransky E; Martin BM; Huang SP
    Nature; 1992 Jun; 357(6377):407-10. PubMed ID: 1594045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gaucher disease in the neonate: a distinct Gaucher phenotype is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene.
    Sidransky E; Sherer DM; Ginns EI
    Pediatr Res; 1992 Oct; 32(4):494-8. PubMed ID: 1437405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.
    Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL
    J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.
    McEachern KA; Nietupski JB; Chuang WL; Armentano D; Johnson J; Hutto E; Grabowski GA; Cheng SH; Marshall J
    J Gene Med; 2006 Jun; 8(6):719-29. PubMed ID: 16528760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebroside storage in normal monocyte cultures.
    Hardy B; Teitelman-Weissman B; Chazan S; Neri A
    Biomed Pharmacother; 1987; 41(1):40-4. PubMed ID: 3607254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease.
    Schiffer V; Santiago-Mujika E; Flunkert S; Schmidt S; Farcher M; Loeffler T; Schilcher I; Posch M; Neddens J; Sun Y; Kehr J; Hutter-Paier B
    PLoS One; 2020; 15(1):e0227077. PubMed ID: 31929594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic mice expressing human glucocerebrosidase variants: utility for the study of Gaucher disease.
    Sanders A; Hemmelgarn H; Melrose HL; Hein L; Fuller M; Clarke LA
    Blood Cells Mol Dis; 2013 Aug; 51(2):109-15. PubMed ID: 23642305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gaucher disease: a lysosomal neurodegenerative disorder.
    Huang WJ; Zhang X; Chen WW
    Eur Rev Med Pharmacol Sci; 2015 Apr; 19(7):1219-26. PubMed ID: 25912581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of neurogenetics in Gaucher disease.
    Brady RO; Barton NW; Grabowski GA
    Arch Neurol; 1993 Nov; 50(11):1212-24. PubMed ID: 8215980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
    Fabrega S; Lehn P
    J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocerebrosidase (Gaucher disease).
    Beutler E; Gelbart T
    Hum Mutat; 1996; 8(3):207-13. PubMed ID: 8889578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of protein-bound epidermal glucosylceramides in beta-glucocerebrosidase deficient type 2 Gaucher mice.
    Doering T; Proia RL; Sandhoff K
    FEBS Lett; 1999 Mar; 447(2-3):167-70. PubMed ID: 10214939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants.
    Sun Y; Quinn B; Witte DP; Grabowski GA
    J Lipid Res; 2005 Oct; 46(10):2102-13. PubMed ID: 16061944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model.
    Marshall J; McEachern KA; Kyros JA; Nietupski JB; Budzinski T; Ziegler RJ; Yew NS; Sullivan J; Scaria A; van Rooijen N; Barranger JA; Cheng SH
    Mol Ther; 2002 Aug; 6(2):179-89. PubMed ID: 12161184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular diagnosis and gene therapy for Gaucher disease].
    Ohashi T
    Nihon Rinsho; 1993 Sep; 51(9):2300-7. PubMed ID: 8411706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gaucher disease.
    Beutler E
    Blood Rev; 1988 Mar; 2(1):59-70. PubMed ID: 3289655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse.
    Hong YB; Kim EY; Jung SC
    J Korean Med Sci; 2006 Aug; 21(4):733-8. PubMed ID: 16891822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.